https://hipa.ai/drug/pembrolizumab/updates/phase-3-primary-completion-nct06687369-2026-08-31 Hipa.ai en 2026-08-31T00:00:00.000Z Pembrolizumab Biosimilar Phase 3 Trial Reaches Primary Completion https://hipa.ai/drug/pembrolizumab/updates/phase-3-primary-completion-nct02954874-2026-08-31 Hipa.ai en 2026-08-31T00:00:00.000Z Pembrolizumab trial reaches primary completion in TNBC https://hipa.ai/drug/nivolumab/updates/trial-results-posted-nct03743766-2026-08-31 Hipa.ai en 2026-08-31T00:00:00.000Z Nivolumab Trial Reports Melanoma Biomarker Measurements https://hipa.ai/drug/pembrolizumab/updates/trial-results-posted-nct05756166-2026-08-31 Hipa.ai en 2026-08-31T00:00:00.000Z Pembrolizumab trial in metastatic TNBC reports no responses https://hipa.ai/drug/itepekimab/updates/trial-results-posted-nct05326412-2026-08-31 Hipa.ai en 2026-08-31T00:00:00.000Z Itepekimab trial reports airway inflammation biomarker changes https://hipa.ai/drug/pembrolizumab/updates/trial-results-posted-nct03457948-2026-08-28 Hipa.ai en 2026-08-28T00:00:00.000Z Pembrolizumab trial reports response in liver metastases https://hipa.ai/drug/rgn-259/updates/trial-results-posted-nct03937882-2026-08-28 Hipa.ai en 2026-08-28T00:00:00.000Z RGN-259 Dry Eye Phase 3 Trial Reports Similar Mean Changes https://hipa.ai/drug/nivolumab/updates/trial-results-posted-nct05500092-2026-08-27 Hipa.ai en 2026-08-27T00:00:00.000Z Nivolumab Trial Reports Pathologic Responses in Lung Cancer https://hipa.ai/drug/mitapivat/updates/boxed-warning-present-label-aqvesme-label-effective-2026-08-2026-08-27 Hipa.ai en 2026-08-27T00:00:00.000Z AQVESME label carries boxed warning for liver injury https://hipa.ai/drug/pembrolizumab/updates/trial-results-posted-nct04303169-2026-08-27 Hipa.ai en 2026-08-27T00:00:00.000Z Pembrolizumab melanoma trial posts near pCR rates up to 19.2% https://hipa.ai/drug/canagliflozin/updates/boxed-warning-present-label-metformin-hydrochloride-label-2026-08-27 Hipa.ai en 2026-08-27T00:00:00.000Z Canagliflozin Label Lists Boxed Warning for Metformin https://hipa.ai/drug/nivolumab/updates/trial-results-posted-nct05625399-2026-08-26 Hipa.ai en 2026-08-26T00:00:00.000Z Nivolumab SC Melanoma Trial Reports Higher Drug Exposure Than IV https://hipa.ai/drug/nivolumab/updates/trial-results-posted-nct05328908-2026-08-26 Hipa.ai en 2026-08-26T00:00:00.000Z Nivolumab Trial Shows Limited Benefit in Later-Line Colorectal Cancer https://hipa.ai/drug/deucravacitinib/updates/trial-results-posted-nct06444399-2026-08-26 Hipa.ai en 2026-08-26T00:00:00.000Z Deucravacitinib PRP trial reports skin-area improvement https://hipa.ai/drug/tirzepatide/updates/fda-approved-supplemental-application-zepbound-tirzepatide-2026-08-26 Hipa.ai en 2026-08-26T00:00:00.000Z Tirzepatide: FDA approves Zepbound supplemental application https://hipa.ai/drug/canagliflozin/updates/boxed-warning-revised-metformin-hydrochloride-label-2026-08-26 Hipa.ai en 2026-08-26T00:00:00.000Z Canagliflozin: Metformin Boxed Warning Revised Aug. 26 https://hipa.ai/drug/empagliflozin/updates/indication-usage-updated-jardiance-label-effective-2026-08-2026-08-26 Hipa.ai en 2026-08-26T00:00:00.000Z Jardiance Label Updates Heart Failure and Kidney Indications